London team helps Jersey with archaeological finds
Jersey Heritage said while the items, found before 1960 at La Cotte de St Brelade, had been subjected to detailed work, the early finds were yet to be studied using modern scientific techniques.
It said visitors could meet the team from the University College London (UCL) Institute of Archaeology for a free "Meet the Collections" event on Saturday at Sir Francis Cook Gallery.
The finds, which are part of a Société Jersiaise collection, include a fragment of woolly mammoth bone and lots of pieces of horse, red deer, bison, and bear bones, said Jersey Heritage.
It added the UCL team was interested in the remains of animals that may have been hunted by some of the last surviving Neanderthal groups in the region.
Jersey Heritage said: "There is no reason why some of these fragments of bone might not be from the Neanderthal people themselves."
More news stories for Jersey
Listen to the latest news for Jersey
Curator of archaeology at Jersey Heritage, Olga Finch, said: "It's great to have the expertise of the London team to undertake this curatorial work and provide a detailed catalogue, which the public and researchers can access to learn more about this important story in the Island's history."
Dr Matt Pope from UCL said it was exciting to be involved in the "important process".
"This is one of the most important collections of Ice Age animal bone in the region and we are getting every ready to unlock its secrets," he added.
Follow BBC Jersey on X and Facebook. Send your story ideas to channel.islands@bbc.co.uk.
Related internet links
Jersey Heritage
UCL Institute of Archaeology
New exhibition to explain history of Jersey
Heritage releases historical Jersey records
Gold award for Jersey Museum exhibit about island
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
"Over the moon!" — Rare and endagered Red Panda twins born at Island zoo
An Isle of Wight zoo has said it is "over the moon" following the birth of rare Red Panda twin cubs. As the mammals are an endangered species, their arrival marks a significant moment for conservation efforts. The cubs were born at Amazon Word on June 17 to mum Xaio and dad Flint. As the cubs are still young and there is always a risk, the zoo has kept the news under wraps — until now. A spokesperson said: "Xiao has done such a fantastic job so far, we are all so proud of her and Flint for helping us play our role as a vital Education and Conservation Centre.." The cubs will remain hidden in the nest boxes until at least three months old and senior staff will continue to monitor the enclosure them via CCTV. Red Pandas are native to the Eastern Himalayas and south western China and are classified as endangered on the IUCN Red List. Their population is declining due to many factors, including habitat loss, human interference and poaching. The zoo said: "Xaio and Flint are part of an International Breeding Programme with zoo's in Europe so that together we can maintain a captive population of this amazing species." "You may not be able to see the cubs at this time but we hope if you can, you'll visit us this summer."
Yahoo
10 hours ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
We recently compiled a list of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It's FDA-approved drug, Rezdiffra (resmetirom), is the first oral, liver-targeted thyroid hormone receptor-β agonist for MASH with moderate to advanced fibrosis (F2–F3). It is also being tested in compensated MASH cirrhosis patients. At the 2025 EASL Congress, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, showing Rezdiffra significantly reduced liver stiffness and lowered the risk of liver decompensation in F4c patients. Notably, 51% of participants had a ≥25% reduction in liver stiffness, and 65% of those with baseline portal hypertension moved to lower-risk categories. Safety remained consistent with prior results. Looking ahead, the MAESTRO-NASH OUTCOMES trial, expected to read out in 2027, will evaluate Rezdiffra's ability to reduce liver-related events in compensated cirrhosis patients. Meanwhile, regulatory momentum continues: the EMA's CHMP issued a positive opinion in June 2025, with potential EU approval expected by August. Rezdiffra would then be the first MASH treatment approved in both the U.S. and Europe. A healthcare professional wearing a health communications device discussing patient data with a colleague. Further solidifying its position, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) secured a new U.S. patent for Rezdiffra's dosing rights in July 2025, enhancing its intellectual property and global commercialization strategy. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
